9,10alpha-二氢-12'-羟基-5'alpha-异丁基-2'-异丙基麦角它曼-3',6',18-三酮甲烷磺酸盐 | 14271-05-7

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 麦角林及其衍生物
• 中文名称: 9,10alpha-二氢-12'-羟基-5'alpha-异丁基-2'-异丙基麦角它曼-3',6',18-三酮甲烷磺酸盐
• 中文别名: 甲磺酸双氢麦角隐亭
• 英文名称: Dihydroergocryptine mesylate
• 英文别名: dihydro-α-ergocryptine；α-dihydroergocornine mesylate；(2R,4R,7R)-N-[(1S,2S,4R,7S)-2-hydroxy-7-(2-methylpropyl)-5,8-dioxo-4-(propan-2-yl)-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(16),9,12,14-tetraene-4-carboxamide mesylate；12'-hydroxy-5'α-isobutyl-2'-isopropyl-(10α)-9,10-dihydro-ergotamane-18,3',6'-trione; methanesulfonate；12'-Hydroxy-5'α-isobutyl-2'-isopropyl-(10α)-9,10-dihydro-ergotaman-18,3',6'-trion; Methansulfonat；dihydro-α-ergocryptine methansulfonic acid；Dihydro-alpha-ergocryptine mesylate；(6aR,9R,10aR)-N-[(1S,2S,4R,7S)-2-hydroxy-7-(2-methylpropyl)-5,8-dioxo-4-propan-2-yl-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide;methanesulfonic acid
• CAS: 14271-05-7；29261-93-6
• 化学式: CH₄O₃S*C₃₂H₄₃N₅O₅
• 分子量: 673.831
• InChiKey: TZGKQIBPZOZAKF-PJLVGBPESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.02
• 重原子数：
  47
• 可旋转键数：
  5
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  181
• 氢给体数：
  4
• 氢受体数：
  9

安全信息

• 危险等级：
  6.1(b)

反应信息

• 作为反应物：
  描述：

  Acid Chromotrope 2R 、 9,10alpha-二氢-12'-羟基-5'alpha-异丁基-2'-异丙基麦角它曼-3',6',18-三酮甲烷磺酸盐 以 二氯甲烷 为溶剂， 生成
  参考文献：
  名称：

  Extractive Spectrophotometric for Determination of Dihydroergocryptine Mesylate in Pharmaceutical Preparations

  摘要：

  本研究建立了简便、准确和高灵敏度的分光光度法，用于快速测定纯品和药物制剂中的甲磺酸双氢麦角新碱。该分光光度法是基于甲磺酸双氢麦角新碱和色原 2R 在酸性缓冲液中形成二元络合物（离子对络合物），呈现紫色。二氯甲烷萃取复合物的吸光度在 531 纳米波长处测定。研究了分析参数对所报告体系的影响。比尔斯定律在 3-180 μg/mL 的浓度范围内均有效，色素 2R 的检出限为 0.08 μg/mL，摩尔吸收系数为 6.8 × 103 L mol-1 cm-1。回收率在 97.20-101.11 % 之间。未观察到其他成分和辅料的干扰。

  DOI：

  10.14233/ajchem.2014.15828

文献信息

• Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
  申请人：The Scripps Research Institute

  公开号：US10660899B2

  公开（公告）日：2020-05-26

  The present invention provides methods of inducing differentiation of oligodendrocyte progenitor cells to a mature myelinating cell fate with a neurotransmitter receptor modulating agent. The present invention also provides methods of stimulating increased myelination in a subject in need thereof by administering said neurotransmitter receptor modulating agent. Methods of treating a subject having a demyelinating disease using a neurotransmitter receptor modulating agent are also provided.

  本发明提供了用神经递质受体调节剂诱导少突胶质祖细胞向成熟髓鞘细胞命运分化的方法。本发明还提供了通过施用所述神经递质受体调节剂刺激有需要的受试者增加髓鞘化的方法。本发明还提供了使用神经递质受体调节剂治疗脱髓鞘疾病的方法。
• MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS
  申请人：Braincells, Inc.

  公开号：EP1991212A1

  公开（公告）日：2008-11-19
• PSYCHO-PHARMACEUTICALS
  申请人：University College Dublin National University Of Ireland, Dublin

  公开号：EP2288345B1

  公开（公告）日：2015-06-10
• DIRECTED DIFFERENTIATION OF OLIGODENDROCYTE PRECURSOR CELLS TO A MYELINATING CELL FATE
  申请人：The Scripps Research Institute

  公开号：EP2675893A1

  公开（公告）日：2013-12-25
• DRUG DEVELOPMENT TARGET PROTEIN AND TARGET GENE, AND METHOD OF SCREENING
  申请人：Yamauchi Tadakazu

  公开号：US20090233274A1

  公开（公告）日：2009-09-17

  The present invention provides novel target proteins and target genes for drug discovery, and the means that enable the development of novel drugs using the same. More particularly, the present invention provides NCS proteins and genes thereof; screening methods for drug (for example, anti-central nervous disease drug); agents for regulating disease (for example, central nervous disease); production methods of a drug derivative; a complex comprising a drug and NCS protein, and a method of producing the complex; a kits comprising a drug or a salt thereof; determination methods for the onset or risk of onset of a specified disease, determination methods for susceptibility to a drug, and determination kits used for the determination methods; and the like.